CN110167559A - 阿匹莫德组合物和将其用于治疗阿尔茨海默病中的方法 - Google Patents

阿匹莫德组合物和将其用于治疗阿尔茨海默病中的方法 Download PDF

Info

Publication number
CN110167559A
CN110167559A CN201780076520.2A CN201780076520A CN110167559A CN 110167559 A CN110167559 A CN 110167559A CN 201780076520 A CN201780076520 A CN 201780076520A CN 110167559 A CN110167559 A CN 110167559A
Authority
CN
China
Prior art keywords
disease
apimod
base
present disclosure
cell
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201780076520.2A
Other languages
English (en)
Chinese (zh)
Inventor
H.利钦斯坦
J.M.罗思伯格
C.康拉德
M.赫尔南德斯
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Artificial Intelligence Therapy Co
Original Assignee
Artificial Intelligence Therapy Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Artificial Intelligence Therapy Co filed Critical Artificial Intelligence Therapy Co
Publication of CN110167559A publication Critical patent/CN110167559A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN201780076520.2A 2016-10-12 2017-10-11 阿匹莫德组合物和将其用于治疗阿尔茨海默病中的方法 Pending CN110167559A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662407186P 2016-10-12 2016-10-12
US62/407186 2016-10-12
PCT/US2017/056147 WO2018071548A1 (en) 2016-10-12 2017-10-11 Apilimod compositions and methods for using same in the treatment of alzheimer's disease

Publications (1)

Publication Number Publication Date
CN110167559A true CN110167559A (zh) 2019-08-23

Family

ID=60268450

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201780076520.2A Pending CN110167559A (zh) 2016-10-12 2017-10-11 阿匹莫德组合物和将其用于治疗阿尔茨海默病中的方法

Country Status (12)

Country Link
US (1) US20190365771A1 (https=)
EP (1) EP3525794A1 (https=)
JP (1) JP7199349B2 (https=)
KR (1) KR20190067824A (https=)
CN (1) CN110167559A (https=)
AU (1) AU2017342262B2 (https=)
BR (1) BR112019007214A2 (https=)
CA (1) CA3039199A1 (https=)
IL (1) IL265911A (https=)
MX (1) MX2019004179A (https=)
RU (1) RU2019113752A (https=)
WO (1) WO2018071548A1 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12589097B2 (en) 2018-02-21 2026-03-31 OrphAl Therapeutics Inc. Apilimod compositions and methods of use
AU2019223014B2 (en) 2018-02-21 2024-10-17 Orphai Therapeutics Inc. Combination therapy with apilimod and glutamatergic agents
CN116059192B (zh) 2019-11-13 2024-10-29 润佳（苏州）医药科技有限公司 同位素富集的3-氨基-1-丙磺酸及其衍生物的用途
KR20220140515A (ko) 2020-01-13 2022-10-18 버지 애널리틱스, 인크. 치환된 피라졸로-피리미딘 및 그의 용도

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012093127A2 (en) * 2011-01-04 2012-07-12 Universität Zürich Modulators of il-12 and/or il-23 for the prevention or treatment of alzheimer's disease
WO2016073871A1 (en) * 2014-11-07 2016-05-12 Lam Therapeutics, Inc. Apilimod for use in the treatment of melanoma
WO2016073877A1 (en) * 2014-11-07 2016-05-12 Lam Therapeutics, Inc. Apilimod for use in the treatment of renal cancer
WO2016118709A1 (en) * 2015-01-23 2016-07-28 Lam Therapeutics, Inc. Anti-viral compositions containing pikfyve inhibitors and use thereof
WO2016126707A1 (en) * 2015-02-03 2016-08-11 Lam Therapeutics, Inc. Apilimod compositions and methods for using same

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7923557B2 (en) 2004-11-10 2011-04-12 Synta Pharmaceuticals Corporation Process for preparing trisubstituted pyrimidine compounds
US7863270B2 (en) 2005-05-13 2011-01-04 Synta Pharmaceuticals Corp. IL-12 modulatory compounds
WO2006128129A2 (en) 2005-05-26 2006-11-30 Synta Pharmaceuticals Corp. Method for treating cancer
US10758545B2 (en) * 2015-06-25 2020-09-01 University Of Southern California Methods to treat neurological diseases

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012093127A2 (en) * 2011-01-04 2012-07-12 Universität Zürich Modulators of il-12 and/or il-23 for the prevention or treatment of alzheimer's disease
WO2016073871A1 (en) * 2014-11-07 2016-05-12 Lam Therapeutics, Inc. Apilimod for use in the treatment of melanoma
WO2016073877A1 (en) * 2014-11-07 2016-05-12 Lam Therapeutics, Inc. Apilimod for use in the treatment of renal cancer
WO2016118709A1 (en) * 2015-01-23 2016-07-28 Lam Therapeutics, Inc. Anti-viral compositions containing pikfyve inhibitors and use thereof
WO2016126707A1 (en) * 2015-02-03 2016-08-11 Lam Therapeutics, Inc. Apilimod compositions and methods for using same

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
YUMIKO WADA等: "Selective abrogation of Th1 response by STA-5326, a potent IL-12/IL-23 inhibitor", 《BLOOD》 *

Also Published As

Publication number Publication date
KR20190067824A (ko) 2019-06-17
RU2019113752A (ru) 2020-11-13
WO2018071548A1 (en) 2018-04-19
AU2017342262A1 (en) 2019-04-18
US20190365771A1 (en) 2019-12-05
IL265911A (en) 2019-06-30
JP7199349B2 (ja) 2023-01-05
BR112019007214A2 (pt) 2019-07-02
RU2019113752A3 (https=) 2021-01-19
EP3525794A1 (en) 2019-08-21
MX2019004179A (es) 2019-09-02
AU2017342262B2 (en) 2023-09-28
CA3039199A1 (en) 2018-04-19
JP2019530711A (ja) 2019-10-24

Similar Documents

Publication Publication Date Title
US11957688B2 (en) Combination therapy with apilimod and glutamatergic agents
US20160287605A1 (en) Combination therapy
EP3177311B1 (en) Drug combinations of cabozantinib with proteasome inhibitor to treat multiple myeloma
US20190192525A1 (en) Apilimod compositions and methods for using same
CN110167559A (zh) 阿匹莫德组合物和将其用于治疗阿尔茨海默病中的方法
US20200306255A1 (en) Compositions and methods for treating niemann pick c disease
CN107249638A (zh) 阿匹莫德用于治疗肾癌
JP2020529995A (ja) 行動の変化の治療方法
BR112012020377B1 (pt) Uso de um composto ou sal farmaceuticamente aceitável do mesmo e embalagem comercial
CN113329749A (zh) 用于治疗葡萄膜黑色素瘤的联合疗法
US20170226063A1 (en) Dna2 inhibitors for cancer treatment
CA3090807C (en) Combination therapy with apilimod and glutamatergic agents
CN115485265A (zh) 8-氯-n-(4-(三氟甲氧基)苯基)喹啉-2-胺的共晶和盐
AU2024316559A1 (en) Apilimod compositions and methods of use

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20190823

WD01 Invention patent application deemed withdrawn after publication